Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...
Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...
Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...
Zacks Investment Research on MSN17h
FDA Grants Accelerated Approval to NVS Kidney Disease DrugNovartis NVS obtains FDA approval of atrasentan, a potent and selective endothelin A (ETA) receptor antagonist, for the ...
Previous research has found that immigrants have lower rates of heart disease, diabetes, dementia and other chronic health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback